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Abstract
Background: Poikiloderma with Neutropenia (PN) is a rare autosomal recessive genodermatosis caused by
C16orf57 mutations. To date 17 mutations have been identified in 31 PN patients.
Results: We characterize six PN patients expanding the clinical phenotype of the syndrome and the mutational
repertoire of the gene. We detect the two novel C16orf57 mutations, c.232C>T and c.265+2T>G, as well as the
already reported c.179delC, c.531delA and c.693+1G>T mutations. cDNA analysis evidences the presence of
aberrant transcripts, and bioinformatic prediction of C16orf57 protein structure gauges the mutations effects on the
folded protein chain.
Computational analysis of the C16orf57 protein shows two conserved H-X-S/T-X tetrapeptide motifs marking the
active site of a two-fold pseudosymmetric structure recalling the 2H phosphoesterase superfamily. Based on this
model C16orf57 is likely a 2H-active site enzyme functioning in RNA processing, as a presumptive RNA ligase.
According to bioinformatic prediction, all known C16orf57 mutations, including the novel mutations herein
described, impair the protein structure by either removing one or both tetrapeptide motifs or by destroying the
symmetry of the native folding.
Finally, we analyse the geographical distribution of the recurrent mutations that depicts clusters featuring a
founder effect.
Conclusions: In cohorts of patients clinically affected by genodermatoses with overlapping symptoms, the
molecular screening of C16orf57 gene seems the proper way to address the correct diagnosis of PN, enabling the
syndrome-specific oncosurveillance.
The bioinformatic prediction of the C16orf57 protein structure denotes a very basic enzymatic function consistent
with a housekeeping function. Detection of aberrant transcripts, also in cells from PN patients carrying early
truncated mutations, suggests they might be translatable. Tissue-specific sensitivity to the lack of functionally
correct protein accounts for the main cutaneous and haematological clinical signs of PN patients.
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Background
Biallelic mutations of the C16orf57 (OMIM*613276)
gene underlie Poikiloderma with Neutropenia (PN;
OMIM#604173), an inherited genodermatosis character-
ized by early onset poikiloderma, pachyonychia, palmo-
plantar hyperkeratosis, skeletal defects and non-cyclic
neutropenia. This condition results in recurrent infec-
tions during infancy and childhood, primarily of a pul-
monary nature, and contributes to the postnatal growth
delay in weight and height of the patients.
The syndrome was first described by Clericuzio in
Navajo Indians [1] and subsequently in patients of Cau-
casian ancestry from different geographic areas [2-5].
Following discovery of the causative gene [6] and mole-
cular evidence for distinct genetic control between PN
and Rothmund-Thomson syndrome (RTS;
OMIM#268400) [7], 31 PN patients have been tested
and found to bear 17 different mutations in the respon-
sible C16orf57 gene, 84% of the patients were found in
the homozygous state [6,8-12] and only six were com-
pound heterozygous [6,11,13]. Interestingly this cohort
includes patients previously diagnosed as affected with
Dyskeratosis Congenita (DC; OMIM#224230) and with
Rothmund-Thomson syndrome illustrating significant
phenotypic overlap among these entities [10,13]. All the
identified mutations, six nonsense, six frameshifts and
five splicing mutations including the apparent missense
change, c.502A>G [6], lead to loss-of-function. Despite
the limited mutational repertoire a few recurrent muta-
tions have been identified, including c.496delA, common
among those of Athabaskan ancestry [11], c.531delA in
Turkish families [10,12] and c.179delC in patients of
North African origin [8,12], consistent with founder
mutations restricted to different geographic areas.
Genotyping further patients could better define the
spectrum, the type and the geographical distribution of
the C16orf57 sequence changes.
The C16orf57 gene is phylogenetically conserved and
ubiquitously expressed, suggesting a housekeeping func-
tion [10].
Whenever cDNA analysis has been performed, mutant
alleles have been detected [6,11] hinting they might be
translatable. The function of the unidentified C16orf57
protein remains obscure, so we focused on bioinformatic
tools to predict the possible structure and ancestry of
C16orf57 and to gauge the functional consequences of
the different mutations on the folded protein chain, a
start point to address genotype-phenotype correlations
in the patients.
In this study we characterize six PN patients and
define at the DNA and cDNA level the underlying
C16orf57 mutations. The mutations all present in the
homozygous state include a novel early truncating
mutation, a novel IVS2 splice-site mutation and an IVS6
splice-site mutation already described but in the hetero-
zygous condition [11].
We also present the computational analysis of the
C16orf57 protein chain, showing that two conserved H-
X-S/T-X tetrapeptide motifs (where X is a hydrophobic
residue) likely mark the active site of a two-fold pseudo-
symmetric structure related to the 2H phosphoesterase
superfamily [14,15]. Based on this analysis we predict
that C16orf57 belongs to this enzyme class and the
effect of all C16orf57 mutations reported so far cause
disruptions of both protein fold and catalytic site that
hold the critical function of the protein.
Methods
Patients
Six patients, three males and three females, referred to
us by clinical geneticists and dermatologists, were
enrolled in this study. Patients and their parents pro-
vided appropriate informed consent.
DNA extraction and mutation analysis
Genomic DNA was isolated from buccal swabs of
patient #26 with NucleoSpin Tissue (Macherey-Nagel,
Bethlehem, PA 18020, USA) and from whole peripheral
blood of patients #11, #16, #17a, #21, #25 and their rela-
tives using the Wizard Genomic DNA Purification Kit
(Promega Corporation, Madison, WI, USA).
About 100 ng of DNA were amplified using GoTaq
polymerase (Promega) with previously published primers
and conditions [6]. Amplicons were sequenced using Big
Dye Terminator v.1.1 Cycle Sequencing Kit according to
the manufacture’s protocol on the ABI PRISM 3130
sequencer (Applied Biosystems, Foster City, CA, USA).
Electropherograms were analyzed with ChromasPro
software 1.42 (Technelysium Pty Ltd, Tewantin QLD,
Australia) using the wild type sequence of C16orf57
gene [ENSG00000103005] as reference.
RNA extraction and RT-PCR analysis
EBV-transformed lymphoblastoid cell lines (LCLs) were
established for patients #21, #17a and their parents.
LCLs were cultured in RPMI 1640 medium with 2 mM
L-glutamine (EuroClone, Milano, Italy) supplemented
with 20% foetal bovine serum (Lonza, Walkersville, MD,
USA) and 1% Penicillin, Streptomycin and Ampicillin in
37°C humidified incubator with 5% CO2.
Total RNA was extracted from LCLs using TRI-Reagent
RNA Isolation reagent (Sigma-Aldrich, Saint-Louis, MI,
USA) and from whole blood of patient #26 using PAXgene
Blood RNA Kit (PreAnalitix, Hombrechtikon, Swiss).
500 ng of total RNA was reverse-transcribed into
cDNA using High Capacity cDNA Reverse Transcription
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Kit (Applied Biosystems) with random hexamers. PCR
amplification of the C16orf57 gene transcripts was per-
formed for patients and positive controls using GoTaq
polymerase (Promega). Specific primers and conditions
for C16orf57 transcripts are listed in additional file 1,
Table S1. Nucleotide sequences were compared to the
major C16orf57 transcript reference sequence
[ENST00000219281].
Computational analysis
An evolutionary and structural profile of C16orf57 was
constructed by iterative PsiBLAST searches of Genbank
[16] followed by PsiPRED secondary structure prediction
of the resulting multiple sequence alignment [17]. This
alignment was also used by HHrep [18] to look for
internally repeated segments of sequence and predicted
structure, and by HHpred to locate potentially related
folds from the PDB by sensitive HMM-HMM compari-
son [19]. Comparative modeling of the C16orf57 three-
dimensional structure from fold recognition-derived
templates was performed by MODELLER [20] and I-
TASSER [21]. Surface patterns of conservation and
variability in the resulting model were derived by Con-
Surf [22]. Structure manipulation and electrostatic
potential surface visualization of C16orf57 and related
structures were done with Pymol http://www.pymol.org.
Results
Clinical findings
The features of the six patients with a suspected PN
clinical diagnosis are listed in Table 1.
The cohort comprises two previously described cases,
one Italian girl (#21) with the association of Osteopetro-
sis with Poikiloderma [23] and one young adult male
(#26) from Turkey diagnosed as Rothmund-Thomson
[24], and four patients of novel description from North
Africa (#11), US (#25) and Turkey (#16, #17a), respec-
tively. The affected sister of case #17a is included as
#17b in Table 1 although her clinical signs are partially
recorded due to premature death.
Pictures of four cases are provided in Figure 1, from
left to right, according to age ranging from early infancy
(#25, panel A), to childhood (#16, panel B), to teen age
(#17a, panel C) to young adulthood (#26, panel D).
The acute phase of the rash is visible in the 5 months
old infant (#25) who displayed, firstly on arms and legs
and subsequently on buttocks and face (Figure 1 A1,
A2), flesh-colored papular changes superimposed on
background scaly erythema. These early skin findings
which have been described at times as ichthyosiform [4]
later evolve into a more characteristic chronic poikilo-
derma visible in all the elder patients (#16, Figure 1 B1,
B2; #17a, Figure 1 C1; #26, Figure 1 D1).
As outlined in Table 1 all our patients have nail dys-
trophy, most often pachyonychia, but anonychia was
observed in one case (#26, Figure 1 D2, D3). The nail
dystrophy progresses from multiple nails with distal
onycholysis involving fingers and toes, as shown in the
infant (#25, Figure 1 A3, A4) to clear-cut pachyonychia
which is present in the two older male patients (#16,
Figure 1 B3; #17a, Figure 1 C2, C3).
Palmo-plantar hyperkeratosis is shared by most cases
as well as a tendency to develop dental caries and tooth
eruption delay (Table 1; Figure 1 B1, C2).
Supplemental skin findings include thin hair (hypotri-
chosis in #21) and actinic-hyperkeratosis of the helix
(#17a).
Craniofacial dysmorphisms include frontal bossing,
saddle nose deformity, midfacial hypoplasia, and retro-
gnathia (Table 1; Figure 1 A1, B1, C1, D1).
Bone alterations (Table 1), detectable on radiograph
[23,24], include osteopenia (#26), severe toe and fingers
dysplasia (#26, Figure 1 D2, D3), osteopetrosis (#21),
calcification and multiple fractures in the long bones
(#11). Delayed skeletal maturation (#21) and small sta-
ture (#16, #17a, #21, #26) are also observed.
Laboratory findings highlight severe, persistent and
non-cyclic neutropenia, leading to recurrent respiratory
infections, which are sometimes resistant to standard
antibiotic treatments. Myelodysplasia and splenomegaly
developed in patient #17a. With regard to sexual devel-
opment, two Turkish males (#17a, #26) presented with
hypogonadism. Cardiac abnormalities were observed in
case #25 and demonstrated both structural (pulmonic
stenosis) and functional abnormalities (ECG alterations).
The family history of case #17a included a miscarriage
and a sibling (#17b) born with a congenital heart defect.
C16orf57 mutations and transcript analysis
The pedigrees of our six PN patients are depicted in
Figure 2 (A, B, C, D, E and 2F): the three patients of
Turkish ancestry are born to consanguineous parents.
The splicing mutation affecting the donor splice site of
IVS6, c.693+1G>T, is detected in homozygous state in
the US infant (#25, Figure 2G).
The two Turkish males, #16 and #17a, carry the same
homozygous deletion c.531delA within exon 5 (Figure
2H). cDNA amplification showed a PCR product of the
expected size and its sequencing confirmed the frame-
shift mutation c.531delA predicting the aberrant protein
p.H179MfsX86 (Figure 2 L, O).
The Italian girl #21 carries the novel homozygous
transition c.232C>T within exon 2 (Figure 2I). Direct
sequencing of the amplified cDNA fragment revealed
the c.232C>T change leading to a premature stop codon
p.R78X (Figure 2 M, P).
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Table 1 Clinical features of the investigated PN patients
Patients #25 #16 #17a #17b #21[23] #26[24] #11
Gender F M M F F M F
Date of
birth
2010 2000 1993 1983-1993 1989 1988 1974
Geographic
origin
US Turkey Turkey Turkey Italy Turkey Algeria
Clinical
signs
poikiloderma yes yes yes yes yes yes yes
onset 5 months 6 months 5 months infancy 6 months 6 months at birth
first localization extremities extremities extremities extremities feet, hands, knee widespread n.d.
photo-
sensitivity
n.d. no no n.d. yes yes n.d.
palmo-plantar
lesions
palmo-plantar
xerotic
erythema
plantar hyper-
keratosis
desquamation
palmo-
plantar
hyper-
keratosis
palmo-
plantar
bullous
changes
palmo-plantar and
knee hyper-keratosis
n.d. palmo-plantar
hyper-
keratosis
nail
abnormalities
multiple nails
with distal
onycholysis
pachyonychia toes nails
subungueal
hyper-
keratosis
n.d. nail dystrophy digit
dystrophy;
toes
anonychya
big toes
dental defects caries
tendency
dental
eruption
delay; caries
tendency
n.d. dental eruption delay n.d. n.d.
craniofacial
dysmorphisms
caput
quadratum;
prominent
forehead
saddle nose saddle-short
nose; flat
broad face;
caput
quadratum;
retrognathia
n.d. saddle nose,
triangular face
maxillary
hypoplasia;
saddle nose;
micrognathia
n.d.
skeletal defects not apparent
at chest X-ray
widening of
femoral
metaphysis
n.d. osteopetrosis at 2 m;
increased bone
density; sclerosis of
vertebrae and skull;
delayed skeletal
maturation
zygodactyly
between 2nd
and 3rd digit;
osteopenia of
all bone
structures
presence of
calcification;
multiple
bone
fractures
haematological
features
neutropenia persistent
leukopenia
leukopenia;
MDS;
splenomegaly
n.d. severe anemia;
neutropenia;
responsive to GCSF
neutropenia neutropenia;
chronic
haemolysis
recurrent
infections
viral hepatitis
(1 month); S.
bovis
bacteremia (3
months)
pneumonia pneumonia;
meningitis
multiple
infections
dental abscess;
severe sepsis;
pneumonia;
broncho-pneumonia
recurrent leg
ulcers with
severe sepsis
infections
since infancy
growth delay n.d. low stature (<
3rd centile)
low stature
(< 3rd
centile)
n.d. low stature low stature n.d.
sexual
development
n.d. normal hypo-
gonadism
n.d. n.d. secondary sex
features poorly
developed;
hypo-
gonadism
n.d.
others pulmonic
stenosis;
prolonged
QT at ECG;
hypoglycemia
n.d. miscarriage;
hyper-
keratosis on
ear helixes;
dry scalp hair
miscarriage;
congenital
heart
disease;
died at 10
years
thin hair n.d. atrophic
polychondritis
n.d. = not detected
Colombo et al. Orphanet Journal of Rare Diseases 2012, 7:7
http://www.ojrd.com/content/7/1/7
Page 4 of 12
The third Turkish patient #26 shows the novel homo-
zygous c.265+2T>G transversion affecting the donor
splice site of IVS2 (Figure 2J). Direct sequencing of the
cDNA fragment evidenced 18 intronic nucleotides
added to exon 2 following the activation of a new cryp-
tic splice site in IVS2 and predicting a premature stop
codon p.Y89WfsX3 (Figure 2 N, Q).
The c.179delC mutation in exon 2 consistent with the
aberrant truncated protein p.P60LfsX54 [8,10] has been
identified in the Algerian female patient (#11; Figure 2K).
Additional file 2 Table S2 sums up the location within
the gene, the type of mutation and the predicted effect
on the C16orf57 protein of the five homozygous muta-
tions detected in the six investigated patients.
Recurrence and geographic distribution of C16orf57
mutations
Four (#25, #16, #17a, #11) of our six patients were
found to carry previously reported C16orf57 mutations
[8,10,11].
A general overview of all 19 C16orf57 mutations
detected so far in 37 molecularly tested PN patients
depicts all recurrent mutations and their geographic dis-
tribution (Figure 3 A, B); 31 out of 37 patients carry
mutations in homozygous state (84%) and only six are
compound heterozygous.
The most frequent recurrent c.531delA mutation is
recorded in the homozygous state in seven patients,
including our patients #16 and #17a from two appar-
ently unrelated Turkish families [12] which originate
from the same rural area. This deletion has been also
reported in five patients of three different families fea-
turing a cluster of Caucasian ethnicity [10] (Figure 3B).
Three more PN patients are of Turkish ancestry [3,25].
The second most frequent mutation c.496delA is iden-
tified in five patients, four homozygous and one hetero-
zygous, from the Athabaskan inbred ethnic group [11].
Our eldest patient of Algerian origin shares the homo-
zygous mutation c.179delC with a described Moroccan
kindred depicting a North African origin of this
Figure 1 Clinical findings of four differently aged PN patients. Panel A refers to the US patient (#25); B, C and D to the Turkish patients #16,
#17a and #26, respectively. Patient #25, the youngest in our cohort shows an erythroderma characterized by background erythema and islands
of relative sparing on face and legs (A1, A2) and distal onycholysis of fingers and toes (A3, A4). Patient #16 face: poikiloderma and carious teeth
are well apparent (B1). Poikiloderma is also visible on the trunk and arm (B2). Pachyonychia of the toes is shown (B3). Facial view of patients
#17a and #26 demonstrating prominent forehead, saddle nose and long philtrum (C1, D1); poikiloderma is evident on the face and on the ear
helix too (C1) and forearm (D2). Plantar hyperkeratosis (C2) and nail thickening (C3) can be seen. Severe malformation of hands and feet with
unhealing ulcers and marked nail dystrophy (D2, D3).
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mutation [4], while the youngest patient of our cohort,
from the US, shares the mutation c.693+1G>T with two
fraternal twins of Scottish origin [11] (Figure 3B).
Three other mutations have been described in unre-
lated patients: the early truncating c.243G>A mutation
in two Mediterranean families in homozygous state
[9,10,26] and in a patient recently reported by a French
group in the heterozygous state [13] (Figure 3B); the
nonsense c.541C>T mutation reported in two unrelated
homozygous patients [10,11] and c.489_492del4 reported
in the heterozygous state in one Navajo/Caucasian and
two Caucasian sibs [11] (Figure 3B).
Bioinformatic prediction of the structure of C16orf57
protein
The unidentified C16orf57 protein sequence lacks
revealing motifs or homologs through database searches
and does not disclose any internal domains by SMART
analysis [27]. As protein structure is better conserved
than sequence, we focused on more sensitive fold recog-
nition and structure prediction tools [28] as a way to
find a fold and related biochemical function for
C16orf57. Iterative PsiBLAST searches [16] were first
used to assemble a phylogenetically diverse set of
C16orf57 paralogs from Genbank. Subsequently, a
PsiPRED-derived secondary structure profile of the
resulting alignment [17] suggested the presence of a a
+b-rich domain in the C-terminal 185 residues of the
C16orf57 chain. Within this conserved domain, the
HHrep web server [18] detected a faint but significant
duplication of sequence and secondary structure pat-
terns, prominently anchored by conserved H-X-T/S-X
tetramotifs that correspond to H120LS122L and
H208LS210L sequences in human C16orf57 (Figure 4A).
Accordingly, HMM-HMM comparisons by HHpred [19]
located a string of significant matches between the
C16orf57 domain (residues 80-265) and diverse mem-
bers of the 2H phosphoesterase fold superfamily that
are characterized by a pseudo-two-fold symmetric a+b
fold with a central, dual histidines (2H) active site [14].
The implication from these fold recognition results is
that C16orf57 is likely a 2H-active site enzyme (Addi-
tional file 3 Figure S1) functioning in RNA processing
pathways, but the low degree of sequence identity (8-
Figure 2 Pedigrees of index cases and genomic and cDNA characterisation of their C16orf57 homozygous mutations. Pedigrees of
patients #25 (A), #16 (B), #17a (C), #21 (D), #26 (E) and #11 (F). Arrows indicate index cases. Direct sequencing of genomic DNA shows
homozygous mutations in all cases: c.693+1G>T affecting the IVS6 donor splice site in patient #25 (G), c.531delA in both patients #16 and #17a
(H), nonsense c.232C>T in patient #21 (I), c.265+2T>G affecting the IVS2 donor splice site in patient #26 (J) and c.179delC in patient #11 (K). L, M,
N show RT-PCR products from patients #17a, #21 and #26, respectively. C+ indicates the positive control with the cDNA source from a healthy
individual; C- indicates the negative control with no cDNA added to the reaction; M indicates the molecular weight markers (Generuler DNA
ladder mix 100 bp-Fermentas). O, P,Q the corresponding sequencing of mutant transcripts.
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14%) in the HHpred alignments do not unambiguously
cluster C16orf57 into one of the four major 2H phos-
phoesterase families: bacterial 2’-5’ RNA ligases, fungal
RNA ligases, plant and yeast 1’,2’-cyclic nucleotide phos-
phodiesterases, or mammalian 2’,3’-cyclic nucleotide
phosphodiesterases (CNPase) [14,29,30]. Still, the high-
est scoring structural matches to C16orf57 are to: a Pyr-
ococcus horikoshii 2’-5’ RNA ligase (PDB file 1VJG) [29],
a central domain from human AKAP18 with a 2H active
site (PDB file 2VFK) [30] that binds AMP, lacks CNPase
activity and resembles bacterial RNA ligase structures;
and the Bacillus subtilis YjcG protein, a putative 2’-5’
RNA ligase (PDB file 2D4G) [31].
To test the structure-based assertion that C16orf57 is
a presumptive RNA ligase, the human C16orf57 2H
phosphoesterase fold was modelled with the top
HHpred match (1VJG) as the template for MODELLER
[20], and also by I-TASSER drawing from multiple
templates [21]. The resulting comparative models are
quite similar (1.42 Å RMSD over 177 aligned Ca
positions), with differences parcelled out to loops and
short helices. The characteristic geometry of the 2H
active site is preserved in C16orf57, with catalytic H120
and H208 residues poised across an active site cleft
between the two symmetric a+b lobes (Additional file
3 Figure S1). Drawing from the common catalytic
mechanism of 2H phosphoesterase structures [29,30],
these enzymes are involved in the hydrolysis of 2’,3’-
or 1’,2’-cyclic phosphates to 2’- or 1’-phosphates. The
histidine residues signature functions either as a
nucleophilic attacking group for the cyclic phosphate
(C-terminal His), or protonate the leaving oxygen in
the reaction (N-terminal His). In bacteria, the 2’-5’
RNA ligase acts to ligate half-tRNA molecules (one
half with a 2’,3’-cyclic phosphate, the other half pre-
senting a 5’-OH terminal). However, similar to the
case of the RNA-ligase-like structure of the human
AKAP18 2H domain [30], the true substrates of the
C16orf57 enzyme remain unknown and await experi-
mental elucidation.
Figure 3 Overview of recurrent C16orf57 mutations. A) Schematic representation of the C16orf57 gene with all sequence alterations so far
identified. B) World map of six recurrent C16orf57 mutations with geographical distribution. Each bullet represents one tested PN patient. A
specific colour is assigned to every mutant allele. Bicolour bullets highlight compound heterozygous patients.
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Predicted effects of all described C16orf57 mutations
according to the 3D model
The 2H phosphoesterase fold of human C16orf57 is
particularly sensitive to the effects of mutations that
cause deletions or truncations in the protein chain
because of the nature of the internal sequence repeats
that are interdigitated between the two structural
repeats or lobes (Figure 4B). These lobes frame the
active site groove and position the two catalytic His
residues, but since the chain topology swaps b-strands
and a-helices between lobes, the linear sequence repeats
are individually incapable of forming a well-folded lobe-
like domain. Since most of the C16orf57 mutations cata-
logued in the present study cause premature termina-
tions of the protein chain (Figure 5), the resulting
protein fragment is either comprised of (a) part of the
N-terminal sequence repeat, (b) exactly the N-terminal
repeat or (c) the complete N-terminal repeat plus some
part of the C-terminal repeat. In all three cases, the
mutant protein is unlikely to fold into a well-structured
lobe; in addition, the frequent loss of the C-terminal
nucleophilic His (Figure 5) further ensures the destruc-
tion of the 2H active site. The two instances of dele-
tions of a protein segment that encompasses b-strand C
(in the N-terminal sequence repeat) would also be
severely disruptive to proper folding of an active protein
(Figure 4B).
Discussion
Since the discovery of the causative gene, Poikiloderma
with Neutropenia syndrome can now be confirmed by
molecular diagnostic testing for mutations in the
C16orf57 gene and thereby differentiated from the phe-
notypically similar clinical entities Rothmund-Thomson
syndrome and Dyskeratosis Congenita. Based on the
molecular test, patients previously diagnosed on clinical
Figure 4 Structural model of C16orf57 protein. A) Predicted 2H phosphoesterase family fold of human C16orf57, built by MODELLER [20]
from the 1VGJ template structure (HHpred match probability of 99.9, E-value 2.9×10-29). Cartoon form with the chain colour-ramped from N-
terminal residue 80 (dark blue) to C-terminal residue 265 (red); b-strands are labelled A-H and a-helices numbered 1-4. B) The two a+b lobes
form an active site groove marked by the signature 2H motifs. Side chains are shown for the catalytic H120xS122 and H208xS210 residues. The
flattened chain topology of human C16orf57 shows the structural repeats (boxed) and active site motifs that characterize the 2H
phosphoesterase fold family. Identical labels and colours are drawn from the structural model in A and B.
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grounds as having RTS or DC have been successfully
reclassified [13].
We have identified biallelic mutations of the C16orf57
gene in six patients including #26, previously described
as atypical Rothmund-Thomson [24] and #21, reported
as affected with Poikiloderma associated with Osteope-
trosis [23]. All the patients herein molecularly confirmed
as PN display the consensus PN clinical signs, i.e. early-
onset poikiloderma involving the extremities and
extending to the face, pachyonychia, palmo-plantar
hyperkeratosis and non-cyclic neutropenia (Table 1). It
is worth mentioning that our patient #17a shows poiki-
loderma also on the ear helix, as previously reported in
other patients [3,9].
Craniofacial dysmorphisms have been reported only in
a few PN patients [5,32]; facial features such as a saddle
nose and midfacial hypoplasia are displayed by four out
of our six patients, suggesting they are quite common
and hence should be recorded during PN clinical evalua-
tion. Dental defects are common in our cases, in agree-
ment with the literature [4,13,26,33]. Hypogonadism was
identified in male patients #17a and #26 and previously
reported [3,34]. In contrast to RECQL4-positive RTS,
where bony changes constitute a major diagnostic sign
[7], skeletal involvement has only seldom been described
in PN patients [3,13,26]. Indeed, apart from our patients
#17a and the infant #25, all herein described PN
patients display overt skeletal signs including zygodac-
tyly between the second and third digit (#26), multiple
bone fractures (#11), intermediate osteopetrosis (#21) or
X-ray detectable skeletal findings (#16) (Table 1). A rela-
tionship may be envisaged between zygodactyly and the
swan neck hand hyperflexibility noticed in a few
described patients [3,5,33]. More generally delayed bone
Figure 5 Structural implications of C16orf57 mutations in PN patients. Predicted disruption of protein structure caused by 19 C16orf57
mutations (references in the first column). The N- and C-terminal sequence repeats detected by HHrep are encoded by similar exon arrays
(exons 2-4 and 5-7, respectively). The correspondence between gene exons and protein domains (using the topology map of Figure 4 with
similar colours and labels) is pointed out focusing on the two H-X-S motifs (grey vertical bars) that form the C16orf57 catalytic site. The top eight
mutations lead to loss of both H-X-S motifs as they predict early truncation by a stop codon (c.232C>T, c.243G>A, c.258T>A and c.267T>A),
frameshift (c.176_177delGG, c.179delC) or missplicing leading to frameshift (c.265+2T>G, c.266-1G>A). Six subsequent mutations terminate the
protein chain before the second H-X-S motif: they include nonsense c.415C>T and c.541C>T, frameshift c.489_492del4, c.496delA and c.531delA
and splice site mutation c.504-2A>C. Two mutations lead to the loss of the second H-X-S domain by inframe exon 6 skipping caused by
frameshift, c.683_693+1del12, or missplicing, c.693+1G>T. Splicing c.450-2A>G and c.502A>G mutations should maintain both the key motifs, but
due to inframe exon 4 skipping the protein loses a critical structural element and likely can not fold properly. Lastly, the c.673C>T stop mutation
predicts a shorter chain endowed with both catalytic motifs, but unable to complete the active structure. Prediction of the effects of the
different mutations is made more complex by the homozygous versus the heterozygous state. Black arrowheads indicate mutations found in the
homozygous state while red arrowheads those found in the heterozygous state; the colour-code of the # symbol is according to the
partnership.
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maturation has been recorded [32] in the girl subse-
quently confirmed to carry two distinct C16orf57 muta-
tions [6], and diffuse osteosclerosis has been underlined
by Porter [26] in the patient found to harbour C16orf57
mutations [10]. This patient is one of three cases
reported as RTS [10] with defects in the bone marrow,
as reported for other clinically diagnosed RTS cases
[32-34]. We believe these cases, previously classified as
affected by RTS, more correctly represent cases of PN
as confirmed by molecular testing of some of them
[6,10]. All our patients display non-cyclic neutropenia,
the hallmark of PN, and this is a fundamental sign dif-
ferentiating PN from both RTS or DC, which should be
searched also in suspected cases where it remains silent
[13]. Neutropenia leads to recurrent infections, which
are widely documented in the paediatric histories of PN
cases and confers upon them a high risk to develop
myelodysplasia from the second decade of life, as
attested in at least ten C16orf57-positive patients [5,10]
and our patient #17a. When considering bone marrow
hypocellularity, increased myeloid precursors and
delayed neutrophils maturation, a higher percentage of
C16orf57-positive cases displays this feature [4,5,10,11]
highlighting the sensitivity of the myeloid lineage to
C16orf57 mutations. Evolution to acute myeloid leuke-
mia has been reported in a few PN patients [10,26] and
in other untested cases [25,33-35]. This evidence fea-
tures PN as a cancer predisposing syndrome affecting
the myeloid compartment and connects PN to RTS, a
syndrome with an increased risk for osteosarcoma and
skin cancer [7], and DC which predisposes to a wide
variety of haematological and solid tumors [36]. Molecu-
lar characterization is thus compulsory for assigning
appropriate oncological surveillance.
As depicted in Figure 3 the recurrence of the c.531delA,
c.496delA and c.179delC mutations delineates three clus-
ters according to the geographic origin of the patients. A
common ancestor is the likely hypothesis to explain the
recurrence of these mutations restricted to specific ethnic
groups, considering the very low frequency of the PN syn-
drome and the prevalence of patients with homozygous
mutations (31 out of 37). Genetic analysis and reconstruc-
tion of ancient genetic links through haplotype segregation
analysis could confirm this assumption.
Expansion of the C16orf57 mutational repertoire and
validation of the observed geographical distribution may
allow assessment of clinical variability of PN phenotype
in distinct founder mutation cohorts, as it has been
described for another autosomal recessive developmen-
tal disorder [37].
Lack of information of the function of C16orf57 pro-
tein makes it difficult to establish a link between muta-
tions and the onset and evolution of syndromic
presentation.
Bioinformatic analysis can provide a preliminary tool
to predict the severity of specific mutations.
The structure-based inference that human C16orf57 is a
member of the 2H phosphoesterase superfamily, despite
very little sequence identity, rests on the recognition of a
common protein fold by sensitive algorithms that weave
together evolutionary information, in the form of sequence
patterns that are conserved across C16orf57 orthologs, and
accurate secondary structure predictions to comprehen-
sively scan structural databases. The most prominent pat-
tern in C16orf57 is a two-fold repeated sequence and
structural segment with signature H-X-T/S-X tetramotifs;
these conserved features are precisely mirrored in the
fold-recognition-derived matches with bilobal 2H phos-
phoesterase folds that rely on the symmetrically poised
His residues for catalytic activity. The 2H phosphoesterase
superfamily is a diverse grouping of enzymes with a com-
mon core architecture, a basic hydrolytic focus for cyclic
phosphates, and some functional variability in both sub-
strates and reactions [14,15]. This degree of functional
diversification is observed in other structurally-assembled
superfamilies of enzymes [38]. Of the various biological
tasks performed by 2H active site enzymes, we argue (by
closer structural resemblance) that C16orf57 is perhaps an
RNA ligase though the actual targets or substrates of this
activity remain unknown.
All the mutations reported in our patients are in the
homozygous state, which facilitates transcript analysis
and understanding the effect of the mutations.
Indeed with the exception of the Algerian patient #11,
transcripts have been tested, detected and sequenced in
all other patients (Figure 2). With regards to the c.693
+1G>T mutation in patient #25, transcript analysis has
been reported [11] suggesting exon 6 skipping according
to the size of the aberrant band; indeed a misspliced 84
base shorter transcript was found associated with the
c.683_693+1del12 which affects the same IVS6 donor
splice site [6]. The general emerging feature is that the
aberrant transcripts are detectable even for early trun-
cating mutations, such as those of patients #21 and #26,
pointing out they are relatively stable and translatable.
Conclusions
It is known that Dyskeratosis Congenita, Rothmund-
Thomson and Poikiloderma with Neutropenia have
many overlapping features. Starting from the clinical
presentation it is very difficult to assess the correct diag-
nosis, and in fact most of the molecularly confirmed PN
patients have a long history of wrong diagnosis, as DC
or RTS. The availability of C16orf57 molecular testing
allows the correct diagnosis which is compulsory for
retargeting syndrome-specific oncosurveillance.
As the present study shows, all the 19 C16orf57 muta-
tions linked to disease involve the predicted enzymatic
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domain of C16orf57 protein. By destroying the native
fold, all mutations should cause a drastic loss of enzy-
matic activity. Future studies of protein presence and
activity in PN patients could confirm whether and how
the aberrant transcripts, which have been always
detected whenever assayed, may be translated.
The C16orf57 gene is ubiquitously expressed [6,10],
but not all tissues are equally affected by the lack of cor-
rectly functioning C16orf57 protein during development
and throughout life.
The onset of the poikiloderma, nail dystrophy and teeth
malformations at early infancy reflects the perturbed mor-
phogenesis of skin and cutaneous annexes, while neutro-
penia results from impaired homeostasis of the highly
C16orf57 expressing myeloid cells [6,10]. The life long risk
of myelodysplastic syndrome features the increased ten-
dency to apoptosis and leukemic transformation of
C16orf57-defective myeloid progenitor cells [39].
However, whether different mutations impact differ-
ently on the clinical phenotype and on the risk of mye-
lodysplastic syndrome awaits further clinical and
molecular characterization of PN patients, along with
delineation of patients’ clinical expressivity in distinct
geographical areas and dissection of the biological func-
tion of the C16orf57 protein.
Additional material
Additional file 1: Primer sequences, amplicons size, annealing
temperatures (Ta) for C16orf57 cDNA analysis (ENST00000219281
Ensembl database) and analysed patients. Table S1 provides technical
information on PCR conditions used to analyze cDNA of PN patients
#17a, #21 and #26.
Additional file 2: C16orf57 homozygous mutations in the set of
investigated PN patients. Table S2 provides a summary of identified
mutations of PN patients including location within the gene, mutation
type and predicted effect on the protein. All mutations are in the
homozygous state.
Additional file 3: Electrostatic potential surface of human C16orf57
predicted protein. The solvent-accessible surface of the I-TASSER-
derived [21] structural model of human C16orf57 was displayed in Pymol
http://www.pymol.org and coloured according to the electrostatic
potential (ESP) ranging from blue (positively charged or basic) to red
(negatively charged or acidic). In a top view that looks directly down at
the active site groove, the corresponding ESP surface is quite negatively
charged, which is similar in nature to 2H phosphoesterase structures of
the RNA ligase class that interact with positively charged substrates
[29,30].
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